Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Operating Income (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Operating Income for 11 consecutive years, with -$98.7 million as the latest value for Q4 2025.

  • Quarterly Operating Income rose 27.66% to -$98.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$441.0 million through Dec 2025, up 17.46% year-over-year, with the annual reading at -$441.0 million for FY2025, 17.46% up from the prior year.
  • Operating Income for Q4 2025 was -$98.7 million at Intellia Therapeutics, up from -$111.5 million in the prior quarter.
  • The five-year high for Operating Income was -$46.4 million in Q1 2021, with the low at -$144.8 million in Q3 2024.
  • Average Operating Income over 5 years is -$110.8 million, with a median of -$111.7 million recorded in 2023.
  • The sharpest move saw Operating Income plummeted 210.71% in 2022, then rose 27.66% in 2025.
  • Over 5 years, Operating Income stood at -$80.4 million in 2021, then plummeted by 36.9% to -$110.1 million in 2022, then dropped by 27.07% to -$139.9 million in 2023, then rose by 2.46% to -$136.4 million in 2024, then rose by 27.66% to -$98.7 million in 2025.
  • According to Business Quant data, Operating Income over the past three periods came in at -$98.7 million, -$111.5 million, and -$110.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.